Episode 6: Veronique Kiermer on open science and a White Negroni

The Translational Mixer

Send us a Text Message.

Veronique Kiermer, Chief Scientific Officer and Executive Editor at the Public Library of Science, talks about the myriad ways in which open science is changing the face of research and some of the challenges it poses for AI and the translational arena.
01:55 What is open science?
03:55 What are barriers to openness?
07:28 Early adopters
10:30 Open challenges for AI
11:35 Registered reports and publication bias
14:20 PLOS’ priorities for open science
18:40 The Open Science Village beyond data access and sharing
24:25 Reproducibility and reuse in drug research
27:30 Can biotech companies be as open as pharma?
29:44 Pre-competitive consortia for rare disease
32:14 Moving the needle
38:00 Professional data curators?
39:53 Opening science around the world
41:05 COVID-19, infectious disease and open science
45:34 Veronique’s favorite tipple
The White Negroni
1 Oz gin
1 Oz Lillet Blanc
1 Oz Suze
DIRECTIONS:
Add ingredients to a mixing glass and stir over ice for 45 seconds. Strain over fresh ice in a rocks glass and garnish with a lemon peel.
Sources mentioned in the podcast
Mehra, MR et al. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet (May 22, 2020) https://doi.org/10.1016/S0140-6736(20)31180-6).
AlphaFold3—why did Nature publish it without its code? Nature 629, 728 (2024). Good question!

Abramson J et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature (8 May 2024).
Promoting reproducibility with registered reports. Nat Hum Behav 1, 0034 (2017). https://doi.org/10.1038/s41562-016-0034

The Yale University Open Data Access (YODA) Project at the Center for Outcomes Research and Evaluation advocates for the responsible sharing of clinical research data

All Trials (https://www.alltrials.net/news/)
Gordon, D.E., Jang, G.M., Bouhaddou, M. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583, 459–468 (2020).
Nature’s podcast on Registered Reports: Nature's Take: Can Registered Reports help tackle publication bias?

The Mixer music “Pour Me Another” courtesy of Smooth Moves!

Chapters

1. Moving the needle (00:00:00)

2. COVID-19, infectious disease and open science (00:00:00)

3. What is open science? (00:01:55)

4. What are barriers to openness? (00:03:55)

5. Early adopters (00:07:28)

6. Open challenges for AI (00:10:30)

7. Registered reports and publication bias (00:11:35)

8. PLOS' priorities for open science (00:14:20)

9. The Open Science Village beyond data access and sharing (00:18:40)

10. Reproducibility and reuse in drug research (00:24:25)

11. Can biotech companies be open as pharma? (00:27:30)

12. Pre-competitive consortia in rare disease (00:29:44)

13. Professional data curators? (00:38:00)

14. Opening science around the world (00:39:53)

15. COVID-19, infectious disease and open science (00:41:05)

16. Veronique's favorite tipple (00:45:34)